A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

@article{Refolo2001ACD,
  title={A Cholesterol-Lowering Drug Reduces $\beta$-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease},
  author={Lorenzo M. Refolo and Miguel A Pappolla and John J Lafrancois and Brian Todd Malester and Stephen D. Schmidt and Tara Thomas-Bryant and G. Stephen Tint and R. Wang and Marc H Mercken and Suzana S. Petanceska and Karen E. Duff},
  journal={Neurobiology of Disease},
  year={2001},
  volume={8},
  pages={890-899}
}
Clinical, epidemiological, and laboratory studies suggest that cholesterol may play a role in the pathogenesis of Alzheimer's disease (AD). Transgenic mice exhibiting an Alzheimer's beta-amyloid phenotype were treated with the cholesterol-lowering drug BM15.766 and tested for modulation of beta-amyloid levels. BM15.766 treatment reduced plasma cholesterol, brain Abeta peptides, and beta-amyloid load by greater than twofold. A strong, positive correlation between the amount of plasma cholesterol… 
View on Elsevier
doi.org
516 Citations
Highly Influential Citations
9
Background Citations
164
Methods Citations
3
Results Citations
7

516 Citations

Citation Type

Citation Type

Alzheimer's disease: the cholesterol connection
TLDR
The identification of a variant of the apolipoprotein E (APOE) gene as a major genetic risk factor for AD is also consistent with a role for cholesterol in the pathogenesis of AD.
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
Cholesterol and statins in Alzheimer's disease: Current controversies
Cholesterol, -amyloid, and Alzheimer's disease
Statins: drugs for Alzheimer’s disease?
TLDR
There is insufficient evidence to suggest the use of statins for treatment in patients with AD, even if many studies do not support elevated cholesterol levels in serum and brain as a risk factor for Alzheimer’s disease.
Statins: drugs for Alzheimer's disease? Review
TLDR
There is insufficient evidence to suggest the use of statins for treatment in patients with AD, even if many studies do not support elevated cholesterol levels in serum and brain as a risk factor for Alzheimer’s disease.
Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease.
Use of in Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease
TLDR
The biology of sterols is described, and how cholesterol may exacerbate the pathogenesis of AD is identified, and treatments aimed at modulating lipid levels may be efficacious in treating AD.
Altered cholesterol metabolism in APP695-transfected neuroblastoma cells
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
TLDR
It is demonstrated that the widely used cholesterol-lowering drugs simvastatin and lovastatin reduce intracellular and extracellular levels of Aβ42 and Aβ40 peptides in primary cultures of hippocampal neurons and mixed cortical neurons, suggesting that lipids are playing an important role in the development of Alzheimer's disease.
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
TLDR
It is proposed that diet can be used to modulate the risk of developing AD and high dietary cholesterol increases Aβ accumulation and accelerates the AD-related pathology observed in this animal model.
Link between heart disease, cholesterol, and Alzheimer's disease: A review
TLDR
Clinical trials testing the benefit of HMG Co‐A reductase inhibitors in the treatment of Alzheimer's disease are underway, and increased β‐amyloid production is also produced by dietary cholesterol in a number of transgenic mouse models of Alzheimer’s disease.
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
TLDR
Aβ immunization reduces both deposition of cerebral fibrillar Aβ and cognitive dysfunction in the TgCRND8 murine model of Alzheimer's disease without, however, altering total levels of Aβ in the brain, which implies that either a ∼50% reduction in dense-cored Aβ plaques is sufficient to affect cognition, or that vaccination may modulate the activity/abundance of a small subpopulation of especially toxic Aβ species.
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol*
TLDR
It is demonstrated that secreted APP processing derivatives and Aβ can be modulated in the brain of an animal by diet and evidence that cholesterol plays a role in the modulation of APP processing in vivo is provided.
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.
TLDR
It is shown that cholesterol is required for Abeta formation to occur and imply a link between cholesterol, Abeta, and Alzheimer's disease.
Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol
TLDR
Hypercholesterolemic rabbits may provide an animal model to study altered beta-APP metabolism leading to Alzheimer-like beta-amyloid accumulation xe03and extracellular deposition in brain.
Apolipoprotein E in the brain and its role in Alzheimer's disease.
  • J. Poirier
  • Biology
    Journal of psychiatry & neuroscience : JPN
  • 1996
TLDR
The role of apoE in the central nervous system (CNS) is particularly important in relation to the function of the cholinergic system which relies to a certain extent on the integrity of phospholipid homeostasis in neurons.
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
TLDR
Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer β-amyloid (Aβ) precursor protein containing a Lys670 → Asn, Met671 → Leu mutation had normal learning and memory but showed impairment by 9 to 10 months of age.
The role of cholesterol in the biosynthesis of beta-amyloid.
TLDR
Changes in APP processing by cholesterol may mediate the way in which the ApoE4 allele increases risk of developing Alzheimer's disease (AD) in western populations.
...
...